Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study

Table 2 The administration of anticancer agents and supportive therapy agents, and the development of TLS by type of therapy

		Total (n = 210)	Developed TLS (n = 17)	No TLS (n = 193)	P-value
(A) Administration of anticancer agents andsupportive therapy agents for TLS prophylaxis
Anti-cancer agents
Number of therapy cycles	Median (Range)
Number of therapy cycles		3 (1–59)	3 (1–11)	3 (1–59)	0.887
Duration of treatment (days)	Mean ± SD
Duration of treatment (days)		150.6 ± 177.4	143.0 ± 119.8	151.3 ± 181.9	0.854
Dose reduction during treatment	No. (%)
Dose reduction during treatment		115 (54.8)	13 (76.5)	102 (52.8)	0.076
Antihyperuricemic agents
Yes ^a	No. (%)	73 (34.8)	7 (41.2)	66 (34.2)	0.600
Allopurinol/ febuxostat		72	7	65
Rasburicase		1	0	1
Hydration
Yes ^b	No. (%)	89 (42.4)	8 (47.1)	81 (42.0)	0.880
Urine alkalization
Yes ^c	No. (%)	131 (62.4)	12 (80.0)	119 (77.8)	1.000
(B) The development of TLS by type of therapy
Bortezomib-containing therapy	No. (%)	130 (61.9)	14 (82.4)	116 (60.1)	0.115 ^e
Intravenously		29	2	27
Subcutaneously		101	12	89
Therapy without Bortezomib ^d		80 (38.1)	3 (17.6)	77 (39.9)

P-values were determined by Mann-Whitney U-test for number of therapy cycles, Fisher’s exact test for categorical variables, and Student’s t-test for continuous variables
SD Standard deviation, TLS Tumor lysis syndrome
^aDefined as being administered prior to the commencement of the primary treatment for multiple myeloma
^bDefined as the average volume over 1000 mL / day for eight days (from one day before to 7 days after the initiation of multiple myeloma primary treatment)
^cDefined as being administered sodium bicarbonate agent before the initiation of multiple myeloma primary treatment
^dTherapies that did not include bortezomib
^eComparison between bortezomib-containing therapy and therapy without bortezomib

ISSN: 1471-2407